** Drug developer Vir Biotechnology's VIR.O shares rise 33.2% to $10.50 premarket
** Co says its drugs VIR-5818 and VIR-5500 showed compelling response in patients with various solid tumors during early-stage trials
** Says VIR-5818 showed tumor shrinkage in 50% of patients with various HER2 positive cancers
** HER2 is a protein that stimulates quick growth of cancer cells
** VIR says all 12 patients who took VIR-5500 showed a decline in prostate-specific antigen levels, which indicate the presence of prostate cancer
** Up to last close, stock down 25.6% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。